Takeda gets a $2.2B deal for its OTC unit as debt-relief drive nears its end

Nicole DeFeudis

Editor

In a big step toward its $10 billion divestment goal, Takeda struck a deal to sell its Japanese consumer healthcare business, known for over-the-counter products …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Takeda gets a $2.2B deal for its OTC unit as debt-relief drive nears its end

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Take­da gets a $2.2B deal for its OTC unit as debt-re­lief dri­ve nears its end

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Takeda gets a $2.2B deal for its OTC unit as debt-relief drive nears its end